A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

ClinicalTrials.gov ID: NCT06326411

Public ClinicalTrials.gov record NCT06326411. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 12:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Open Label Single-arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

Study identification

NCT ID: NCT06326411
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Nested Therapeutics, Inc; Industry
Enrollment: 230 participants

Conditions and interventions

Conditions

Interventions

NST-628 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 8, 2024
Primary completion: Oct 31, 2028
Completion: Oct 31, 2029
Last update posted: Apr 19, 2026

2024 – 2029

United States locations

U.S. sites: 17
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	Recruiting
UCLA Hematology/Oncology	Westwood, Los Angeles	California	90024	Recruiting
Sarah Cannon Research Institute at Health ONE	Denver	Colorado	80218	Recruiting
Yale Cancer Center	New Haven	Connecticut	06511	Completed
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Roswell Park	Buffalo	New York	14263	Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	New York	New York	10016	Recruiting
Columbia University Medical Center	New York	New York	10032	Recruiting
Memorial Slone Kettering Cancer Center	New York	New York	10065	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	37203	Recruiting
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	Recruiting
NEXT Oncology - Austin	Austin	Texas	78758	Active, not recruiting
NEXT Oncology - Dallas	Dallas	Texas	75039	Active, not recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
START Moutain Region	West Valley City	Utah	84119	Completed
NEXT Oncology - Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06326411, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2026 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06326411 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →